CTOs on the Move

Orb Health

www.orbhealth.com

 
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.orbhealth.com
  • 610 East Roosevelt Street Suite 134
    Phoenix, AZ USA 85004
  • Phone: 602.606.8927

Executives

Name Title Contact Details
Tyler Downs
 Chief Technology Officer Profile
Jerry Kizziar
 Chief Technology Officer Profile
Jerry Kizziar
 Chief Technology Officer Profile

Similar Companies

Knack Global

Knack Global is a Woodbridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Health and Rejuvenation Center

The Health and Rejuvenation Center is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Master Train Inc

Master Train Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tennessee Heart and Vascular

Tennessee Heart and Vascular is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Hendersonville, TN. To find more information about Tennessee Heart and Vascular, please visit www.tennheart.com

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.